Xcout IntelNervGen Pharma Corp.
NervGen Pharma Corp. is a biotechnology enterprise currently in its clinical development phase, focused on devising therapeutic solutions for nerve injuries and progressive neurodegenerative diseases. Their innovative approach centers on deactivating the natural biological mechanisms that typically impede the nervous system's ability to repair itself.
Subscribe to see NervGen Pharma Corp.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
NervGen Pharma Corp. at a glance
NervGen Pharma Corp. is a biotech company headquartered in West Vancouver, Canada. It is publicly listed (NGEN) with a market capitalisation of $134M. Xcout tracks 11 named people at NervGen Pharma Corp., including Adam H. Rogers (President, CEO & Chairman).
NervGen Pharma Corp. leadership
- Adam H. RogersPresident, CEO & Chairman
- Keith A. VendolaChief Financial Officer
- Randall E. KayeChief Medical Advisor & Director
- Shamim RuffChief Regulatory Affairs Officer
- Harold Martin PunnettCo-Founder & Independent Director
- Charles V OlsonSenior Vice President of Technical Operations
5 more named people on record for NervGen Pharma Corp., with roles, board committees and tenure — see the full roster →
Investors
NervGen Pharma Corp. competitors
A few of NervGen Pharma Corp.'s closest competitors — see the full list of competitors and alternatives →
FIVE DISCOVERY Corp is a biotechnology company that develops non-hallucinogenic neuroplastogen therapeutics designed to repair and stabilize dysfunctional neural circuits. The company serves patients suffering from neurodegenerative conditions and brain injuries, including Alzheimer's disease, Parkinson's disease, and traumatic brain injury.
Neurasic Therapeutics is a biotechnology company headquartered in Montreal, Canada, created to advance groundbreaking research into novel therapeutics.
NovaGo Therapeutics is a clinical-stage Swiss biotech company located in Schlieren that develops human antibody therapeutics focused on nerve growth and regeneration.
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Asceneuron is a biotechnology research company founded in 2012 and headquartered in Eysins, Switzerland, focusing on the discovery and development of therapeutics for neurodegenerative disorders.
Get NervGen Pharma Corp.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on NervGen Pharma Corp. in Xcout Intel
- 11 named people with titles, LinkedIn and board committees
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access